Non-prescription availability of low-dose codeine products

https://policybase.cma.ca/link/policy13734

**POLICY TYPE**  
Response to consultation

**DATE**  
2017-11-7

**TOPICS**  
Pharmaceuticals, prescribing, cannabis, drugs

**Documents**

Submission to the Health Canada consultation on the potential risks, benefits and impacts of changes to the regulations to the Controlled Drugs and Substances Act that would require all products containing codeine to be sold by prescriber only.

November 7, 2017
CMA response to patented medicines regulations consultations
https://policybase.cma.ca/link/policy13690

POLICY TYPE
Response to consultation

DATE
2017-06-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

---

Canada’s lower-risk cannabis use guidelines (LRCUG)
https://policybase.cma.ca/link/policy13726

POLICY TYPE
Policy endorsement

DATE
2017-05-26

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13641

POLICY TYPE: Parliamentary submission

DATE: 2017-04-07

TOPICS: Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA submission to the study of Bill C-37
https://policybase.cma.ca/link/policy13617

POLICY TYPE          Parliamentary submission
DATE                2017-04-06
TOPICS              Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on the renewal of Federal Tobacco Control Strategy

https://policybase.cma.ca/link/policy13804

POLICY TYPE
Response to consultation

DATE
2017-04-05

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

April 5, 2017

Commissioned by the Federal Tobacco Control Initiative

Dear [Name],

I am responding on behalf of the Canadian Medical Association (CMA) to your request for consultation on the renewal of the Federal Tobacco Control Strategy (FTCS) and on the development of a National Tobacco Control Strategy for Canada. This is an initiative of the Canadian Coalition on Smoking & Health (CCSH) and an extension of the provisions of the Tobacco Act.

The latest Canadian Tobacco Use Surveys (CTUS) report that 20% of the population aged 14 and older are current smokers. In addition, 32% of the population over 14 years old experience some exposure to secondhand smoke. As we approach the 2018 national smoke-free benchmark of 10% of smokers, we must continue to work together to find solutions to the problems we face.

We support the Government's goal of less than 5% of current adult smokers by 2019. It must be recognized that specific subpopulations, such as indigenous populations, will require different policies and strategies to achieve this goal. This must be done in partnership with these communities.

The reduction of tobacco use in Canada is important not only for health reasons but also for economic reasons. Tobacco use is a significant contributor to health care costs, which are expected to rise in the coming years.

The CMA believes that smoking cessation is, in almost all cases, the healthiest option. We believe that tobacco control is a matter of public health and that all levels of government must do their part to reduce tobacco use. We are pleased to be able to offer our consultation on the renewal of the FTCS.

Yours sincerely,

Canadian Medical Association

CMA Policybase - Canadian Medical Association  p. 6
Position statement on prescription drug shortages in Canada

https://policybase.cma.ca/link/policy10756

POLICY TYPE
Policy document

LAST REVIEWED
2017-03-04

DATE
2013-05-25

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Regulation of Self-Care Products in Canada

https://policybase.cma.ca/link/policy13802

POLICY TYPE  Response to consultation
DATE          2016-10-31
TOPICS        Pharmaceuticals, prescribing, cannabis, drugs
               Health care and patient safety

Documents
Statement to the House of Commons Committee on Health addressing the opioid crisis in Canada
https://policybase.cma.ca/link/policy13936

POLICY TYPE
Parliamentary submission

DATE
2016-10-18

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health
Health care and patient safety

Documents
Legalization, regulation and restriction of access to marijuana
https://policybase.cma.ca/link/policy11954

POLICY TYPE  Response to consultation
DATE  2016-08-29
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission
Legalization, Regulation and Restriction of Access to Marijuana

Government of Canada – Task Force on Marijuana Legalization and Regulation

August 29, 2016

STATEMENT  DECLARATION

Chief Statement - Application of Evidence

Dear Minister of Health, Gentleman:

The Canadian Medical Association (CMA) is pleased to provide this information to the Task Force on Marijuana Legalization and Regulation. The information provided represents evidence on the harms to public health related to marijuana use.

1. Introduction

The task force has requested evidence on the harms to public health related to marijuana use. CMA provides a summary of harms to public health related to marijuana use.

2. Sample size

Many of the studies included in this report have used samples from Canada. The majority of studies have used samples from the general population, with some using specific populations (e.g., pregnant women).

3. Effects on health

The majority of studies included in this report have used samples from Canada. The majority of studies have used samples from the general population, with some using specific populations (e.g., pregnant women).

4. Conclusions

CMA recommends that governments consider the evidence and harms related to marijuana use before making decisions on legalization.

For information: info@cmaj.ca  1-800-668-1585

CMA Policybase - Canadian Medical Association
Health Canada’s Consultation on “Plain and Standardized Packaging”
https://policybase.cma.ca/link/policy13817

POLICY TYPE
Response to consultation

DATE
2016-08-12

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
National pharmacare in Canada: Getting there from here
https://policybase.cma.ca/link/policy11959

POLICY TYPE          Parliamentary submission
DATE                2016-06-01
TOPICS              Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on the prescription drug list: Naloxone
https://policybase.cma.ca/link/policy11847

POLICY TYPE  Response to consultation
DATE  2016-03-19
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Regulatory framework for the mandatory reporting of adverse drug reactions and medical device incidents by provincial and territorial healthcare institutions.

https://policybase.cma.ca/link/policy11814

POLICY TYPE  Response to consultation
DATE  2016-01-20
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
CMA’s Response to Health Canada’s Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law)
https://policybase.cma.ca/link/policy11599

POLICY TYPE
Response to consultation

DATE
2015-06-08

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Harms associated with opioids and other psychoactive prescription drugs

https://policybase.cma.ca/link/policy11535

POLICY TYPE Policy document
DATE 2015-05-30
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)
https://policybase.cma.ca/link/policy11297

POLICY TYPE
Parliamentary submission

DATE
2014-10-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents